<DOC>
	<DOCNO>NCT01730469</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( PK ) study single dose 150 mg AT1001 ( migalastat HCl , GR181413A ) administer orally healthy subject normal renal function subject mild , moderate , severe renal impairment .</brief_summary>
	<brief_title>Safety Pharmacokinetics AT1001 ( Migalastat HCl ) Healthy Subjects Subjects With Impaired Renal Function</brief_title>
	<detailed_description>This open-label , non-randomized , multiple-center , sequential group , safety , tolerability , PK study single dose AT1001 ( migalastat HCl , GR181413A ) administer orally 150 mg dose fast healthy control male female subject normal renal function compare mild , moderate , severe renally-impaired subject ( classified level creatinine clearance [ CLcr ] determine Cockcroft-Gault formula ) . Screening occur Day -28 Day -2 . Subjects check-in clinic Day -1 receive single oral dose 150 mg AT1001 Day 1 . Subjects discharge clinic Day 2 ( stable determine Investigator ) return daily visit Day 3 Day 6 safety assessment PK sampling . Subjects undergo follow-up visit Day 7 ( +1 ) end study visit Day 10 ( +1 ) .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion Criteria All subject male female age 18 70 year inclusive ( subject normal renal function , mild moderate renal impairment ) , 18 75 year inclusive ( subject severe renal impairment ) body mass index 18.0 40.0 kilogram ( kg ) /square meter ( m^2 ) inclusive female nonpregnant , nonlactating , postmenopausal &gt; =1 year , surgically sterile &gt; = 90 day , agree use approve method contraception male sterile use approve method contraception understand sign informed consent form Healthy subject normal renal function negative test select drug abuse ( excludes alcohol ) Screening Checkin good health clinically significant medical history , physical examination , vital sign , 12lead ECG clinical laboratory test within reference range clinically significant normal renal function ( estimate CLcr &gt; 90 mL/min ) Screening Subjects mild , moderate severe renal impairment negative test select drug abuse ( excludes alcohol ) Screening Checkin verification prescription positive test renal impairment ( estimate CLcr &lt; 90 mL/min ) evidence stable renal impairment define two separate estimate CLcr value within 25 % clinical laboratory result consistent renal condition clinical significance study abnormal laboratory value must clinically significant . Anemia secondary renal disease acceptable hemoglobin â‰¥9 g/dL clinically significant symptom . Liver enzymes bilirubin must twice upper normal level subject renal impairment must stable underlying medical condition &lt; 90 day study start stable medication regimen ( ) ( new drug ( ) change dosage ( ) &lt; 30 day study drug ) good general health , allow concurrent illness associate chronic kidney disease All subject : history hypersensitivity allergy drug , unless approve Investigator review Sponsor/Medical Monitor participation study receipt investigational drug &lt; 5 halflives 30 day ( whichever longer ) Checkin use alcohol , grapefruit , caffeinecontaining food beverage &lt; 72 hour Checkin , unless approve Investigator review Sponsor/Medical Monitor poor peripheral venous access whole blood donation &lt; 56 day dose plasma donation &lt; 14 day dose receipt blood product &lt; 2 month Checkin history presence clinically significant abnormal ECG history alcoholism drug addiction &lt; 1 year Checkin positive test HIV antibody , HBsAg antiHCV pregnant breastfeed Healthy subject normal renal function : use tobacco nicotinecontaining product &lt; 6 month Checkin clinically significant ( history active ) cardiac , hepatic , pulmonary , endocrine , neurological , infectious , gastrointestinal , hematologic , oncologic , psychiatric disease put subject increase risk could interfere study objective screen laboratory value outside normal range deem clinically significant Investigator use prescription drug &lt; 14 day dose nonprescription drug &lt; 7 day dose need concomitant medication study Subjects mild , moderate , severe renal impairment : unstable disease ( concurrent medical condition change significantly &lt; 90 day ) change concomitant prescription medication &lt; 30 day dose expect change study use new nonprescription medication &lt; 30 day dose renal transplant acute chronic nonrenal condition limit subject 's ability complete and/or participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GR181413</keyword>
	<keyword>Safety</keyword>
	<keyword>AT1001</keyword>
	<keyword>Migalastat hydrochloride</keyword>
</DOC>